|
|
View Clinical Trial (Medical Research Study)
|
Effects of Bariatric Surgery on Insulin - NCT00535600-85014 (Clinical Trial 186194)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy186194.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Phoenix |
|
State:
|
|
AZ |
| Zip Code: |
|
85014 |
| Conditions: |
|
Obesity - Bariatric Surgery - Gastric Bypass - Weight Loss - Hyperglycemia |
| Purpose: |
|
This study, conducted at the NIH Clinical Research Unit (CRU) at the Phoenix Indian Medical
Center, will compare the effects of two methods of bariatric surgery, the adjustable BAND
and Roux-en-Y gastric bypass, on insulin. Bariatric surgery is a treatment for achieving and
maintaining weight loss. The study will look at how this surgery might improve how insulin
(a hormone important for regulating blood sugar levels) is made and works in the body and
the possible role of changes in other hormones produced by the gut (stomach and intestines).
People between 18 and 50 years of age who are scheduled to have either laparoscopic
adjustable BAND or Roux-en-Y gastric bypass surgery may be eligible for this study.
Candidates are screened about 4 to 6 weeks before their surgery with a medical history,
blood tests and an oral glucose tolerance test for diabetes.
Participants spend 4 days at the CRU or 2 days overnight and an out-patient visit
approximately 4 to 6 weeks before their surgery and again 3 to 6 weeks after their surgery.
They return for a 4-6 hour visit at the CRU at 6 months, 1 and 2 years after surgery and for
half-day outpatient visits at 3, 4 and 5 years after surgery for the following procedures:
- Blood and urine tests, including a pregnancy test for women. (4-day and 2-day
admissions and years, 3, 4 and 5)
- DEXA, an x-ray scan to determine body fat content. (4-day and 2-day admissions and
years, 3, 4 and 5)
- MRI scan to measure fat tissue in the abdomen. (4-day and 2-day admissions and years,
3, 4 and 5)
- Intravenous (I.V.) glucose tolerance test for risk of obesity and diabetes. A sugar
solution is given through a needle in a vein of one arm and blood samples are drawn
through another needle in a vein in the other arm. (4-day admissions)
- Meal test to measure blood sugar and insulin and gut hormone levels after a meal. After
an I.V. line is placed in an arm vein, the subject eats breakfast over 20 minutes.
Blood samples are collected halfway through the meal, at the end of the meal, and at
15, 30, 60, 90, 120 and 180 minutes after completing the meal. Subjects fill out
questionnaires on feelings of hunger and fullness before, during and after the meal
test. (4-day and 2-day admissions)
- Glucose clamp test to measure the effect on the body of insulin given through a vein.
An I.V line is placed in a vein in the arm and in a vein of the hand on the other side
of the body. While insulin is infused through one I.V., blood sugar levels are checked
every 5 minutes and a sugar solution is given into a vein as needed. A radioactive
sugar is also infused very slowly over 4 hours to determine how much sugar the body
produces by itself. (4-day admissions)
|
| Study summary: |
|
Bariatric surgery is a treatment for obesity that, in many cases, also improves fasting
blood sugar levels even in patients with type 2 diabetes (T2DM) - within days or weeks after
sugery. Both inability to use insulin (insulin resistance) and inability to make enough
insulin when needed (impaired insulin secretion) must be present for T2DM to occur, and both
have been reported to improve after bariatric surgery. It is generally thought that the
immediate improvement in blood sugar levels, including remission of T2DM or "prediabetes" in
many patients, following bariatric surgery is due to the markedly reduced intake of
calories. However, it is not known why blood sugar levels before and after meals tend to
improve earlier and to a greater extent in patients who have a Roux-enY gastric bypass
(RYGB) procedure than in patients who have either the adjustable gastric banding (BAND) or
sleeve gastrectomy (SG) procedure. It has been proposed that the surgical alteration of the
gut and subsequent re-routing of food that occurs with RYGB procedure results in unique
changes in how the gut and pancreas (the organ that secretes insulin) respond to food and
that these changes are also related to improved insulin resistance and/or secretion.
The purpose of this protocol is to study, before and after surgery, volunteers who either
have normal or impaired ("pre-diabetic") blood sugar regulation and who have been approved
to undergo either elective RYGBP, BAND or SG bariatric surgery (n=16 each per surgery group,
total = 48 individuals with normal blood sugars; n= 10 each per surgery group, total = 30
individuals with prediabetes). The primary aims are to compare the early effects of the
BAND, SG and RYGBP on: a) the ability to maintain blood sugar levels, b) how much insulin is
made (secretion) and works (insulin action) in the body, and c) responses of gut and
pancreas hormones to a meal test before any significant weight loss occurs after surgery. To
achieve these goals, we initially will screen volunteers at the NIH Clinical Research Unit
in Phoenix approximately 4-6 weeks prior to surgery (1-day outpatient visit) to determine
oral glucose tolerance status (OGTT). Within 3 weeks (1-4 weeks prior to surgery), subjects
will then be admitted (4-day in-patient stay) or a 2 day overnight stay and an outpatient
(4-6 hour) visit to measure weight, body fatness (DXA scan), waist circumference, insulin
resistance, insulin secretion, fasting blood sugar and hemoglobin A1c (HbA1c; a substance
that indicates how well the body keeps overall blood sugar levels in a normal range), and
plasma hormone responses of the gut and pancreas to a standard meal test. These measurements
will be repeated at 3-6 weeks following surgery.
Secondary aims are to: 1) compare long-term effects (up to 5 years) of BAND, SG or RYGBP
surgery on fasting blood sugar and HbA1c levels, 2) determine if these levels are related to
the responses of gut and pancreas hormones during a meal test, and 3) determine whether
pre-op or early post-op measures of insulin secretion, insulin action, or responses of gut
and pancreas hormones to a meal can predict long-term levels of fasting blood sugar and
HbA1c after accounting for changes in weight or body fat. To achieve these goals, subjects
will be re-admitted to the NIH CRU (out-patient, 4-6 hour visit) at 6, 12, and 24 months
after surgery to have repeat measurements of body weight, fatness (DXA, non-contrast MRI of
waist and thigh), waist circumference, fasting blood sugar and HbA1c levels and the gut and
pancreatic hormone responses to a meal test. Thereafter, subjects will have annual
outpatient measurements of body weight, body fat and fasting blood sugar and HbA1c levels at
3, 4 and 5 years after surgery. |
| Criteria: |
|
- INCLUSION CRITERIA:
- Subjects must initially qualify for bariatric surgery according to current NIH
guidelines, which require the presence of either morbid obesity alone (BMI greater
than 40 kg/m(2)) or a BMI greater than 35 kg/m(2) along with at least 2 other
co-morbidities.
- Patients with conditions such as sleep apnea, mild steatohepatitis, GERD, asthma (not
requiring oral steroids) and osteoarthritis can be considered for participation.
- Subject with undiagnosed diabetes (2-h glucose greater than 200 mg/dl during initial
screening OGTT) will be included in the IGR group ONLY IF BOTH fasting plasma glucose
is less than 126 mg/dl and HbA1c is less than 7 percent, suggesting early T2DM.
- Subjects must be at least 18 years of age and less than 150 kg body weight.
- Males and females of all ethnic minorities will be included.
EXCLUSION CRITERIA:
Because of the indications for bariatric surgery, many potential subjects will have
underlying co-morbidities associated with obesity. For this protocol, subjects will be
excluded for the following:
- Current smoking
- Previously diagnosed diabetes
- Other endocrine disorders, such as Cushing's disease, pituitary disorders, and
thyroid disease
- Significant hepatic or renal disease (ALT and AST greater than 3-fold above upper
limit of normal range, cirrhosis, active hepatitis B or C, serum creatinine greater
than 1.5 mg/dl or presence of protein in urine dipstick)
- Active tuberculosis (self-report)
- Major pulmonary disorders including physician diagnosed chronic obstructive pulmonary
diseases other than obstructive sleep apnea
- Cardiovascular diseases, including coronary heart disease, heart failure,
arrhythmias, and peripheral artery disease
- Hypertension (according to the World Health Organization diagnostic criteria),
treated or uncontrolled
- Gastrointestinal disease, including inflammatory bowel diseases (e.g. Crohn's disease
and ulcerative colitis), malabsorption syndromes (e.g. celiac disease), gastric ulcer
(active)
- Central nervous system disease, including previous history of cerebrovascular
accidents, dementia, and neurodegenerative disorders
- Cancer requiring treatment in the past five years, except for non-melanoma skin
cancers or cancers that have clearly been cured or in the opinion of the investigator
carry an excellent prognosis
- Psychiatric conditions or behavior or current alcohol or illicit drug use that would
be incompatible with safe and successful participation in this study
- Recent use (within 30 days) of anorexiant medications, antibiotics, contraceptives or
fertility drugs or recent use (within 5 days) of anti inflammatory agents
- Pregnancy or breastfeeding (to avoid radiation exposure to fetus or nursing infant) |
|
|
|
| Study is available at: |
|
NIDDK, Phoenix
Phoenix, AZ 85014
United States
Primary Contact:
Joy C. Bunt, M.D.
Email: jbunt@phx.niddk.nih.gov
Phone: (602) 200-5312 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 15, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|
|
|
|